2017年9月1日 · Discovery of vimseltinib (DCC -3014), a highly selective switch -control inhibitor of CSF1R kinase. Phase 1 Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, …

2022年10月15日 · Structure Activity Relationship optimization in a novel series of dihydropyrimidone-based CSF1R kinase inhibitors led to the discovery of compound 20 (DCC …

2022年10月15日 · Starting with lead compound 3, an SAR optimization campaign led to the discovery of vimseltinib (DCC-3014; compound 20) currently undergoing clinical evaluation for …

vimseltinib (DCC-3014), a highly selective switch-control inhibitor of CSF1R kinase Timothy M. Caldwell, Yu Mi Ahn, Gary E. Brandt, Lara E. Davis, Michael Kaufman, Keisuke Kuida, Cynthia …

2024年8月16日 · The FDA has accepted and granted priority review to a new drug application (NDA) for vimseltinib (DCC-3014), a colony-stimulating factor 1 receptor (CSF1R)-directed …

DCC-3014 –Highly Selective CSF1R Kinase Inhibitor 3 •DCC-3014 is a highly selective, oral, investigational switch control kinase inhibitor that exhibits nanomolar potency for CSF1R with …

2021年5月28日 · DCC-3014 is an inhibitor of the CSF1R kinase that decreases tumor infiltrating myeloid cells in preclinical models. We hypothesized that DCC-3014 combined with the anti …

• DCC-3014 is an orally administered, potent, and selective inhibitor of CSF1R that was engineered to bind into the CSF1R switch pocket and inhibit kinase activity5 – DCC-3014 …

2017年6月1日 · Deciphera is scheduled to reveal updated phase 1 data on its tumor resistance-targeting candidate DCC-2618 at the big oncology meeting in Chicago, and said it will use the …

Vimseltinib, also known as DCC-3014, is an investigational drug that works as a colony-stimulating factor 1 receptor (CSF1R) inhibitor. It is being studied for its potential to treat …